Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Roche's Fenebrutinib Significantly Reduces Relapses in RMS Phase 3 Trials

Roche announced positive Phase III FENhance 1 and 2 study results for fenebrutinib in relapsing multiple sclerosis (RMS). The investigational non-covalent BTK inhibitor met its primary endpoint, significantly reducing the annualised relapse rate (ARR) by 51.1% in FENhance 1 and 58.5% in FENhance 2 compared to teriflunomide over 96 weeks. This translates to patients experiencing approximately one relapse every 17 years. Fenebrutinib also showed significant reductions in brain lesion activity and positive trends in reducing disability progression. The data supports fenebrutinib's potential as a high-efficacy oral treatment for RMS, with regulatory submissions planned for both RMS and PPMS data.

• Fenebrutinib demonstrated superior efficacy in reducing relapses, achieving a 51.1% reduction in ARR in FENhance 1 (p<0.001) and 58.5% in FENhance 2 (p<0.0001) compared to teriflunomide. This translates to a substantial improvement, with patients experiencing approximately one relapse every 17 years, significantly extending relapse-free periods for patients with relapsing multiple sclerosis.
• The studies showed fenebrutinib significantly reduced markers of active inflammation (new T1-Gd+ lesions) by 70.7% and 77.6% and chronic disease burden (new/enlarging T2 lesions) by 76.0% and 82.5% in FENhance 1 and 2, respectively (all p<0.0001). Additionally, positive trends were observed in reducing 12-week composite confirmed disability progression (cCDP12) by 20% and 13%.
• Fenebrutinib exhibited a safety profile with liver enzyme elevations and infection rates comparable to teriflunomide. While an imbalance in fatalities was noted (7 in fenebrutinib vs 1 in teriflunomide), the overall data, including previous positive results in PPMS, positions fenebrutinib as a potential first-in-class, high-efficacy oral BTK inhibitor for both RMS and PPMS, with regulatory submissions anticipated.

Fenebrutinib's Superiority in Reducing RMS Relapses and Lesions

Recent clinical studies have demonstrated fenebrutinib's remarkable efficacy in controlling disease activity in relapsing multiple sclerosis. The FENopta phase 2 trial, a multicentre, double-blind, randomised, placebo-controlled study conducted across 18 centers in six countries, evaluated fenebrutinib 200 mg twice daily versus placebo in 109 patients with relapsing MS. The study achieved its primary endpoint with a striking 69% relative reduction in new T1 gadolinium-enhancing lesions at weeks 4, 8, and 12 compared to placebo (0.077 versus 0.245, p=0.0022). This BTK inhibitor demonstrated sustained efficacy during the open-label extension, with an unadjusted annualised relapse rate of only 0.04 through week 48, and 96% of patients remaining relapse-free.

The safety profile of fenebrutinib proved favorable throughout the study period. The most commonly reported adverse events in the fenebrutinib group included hepatic enzyme elevations (6% versus 0% placebo), headache (4% versus 3% placebo), and nasopharyngitis (3% versus 0% placebo). Notably, no serious adverse events or deaths occurred during the 12-week double-blind period, establishing fenebrutinib as a well-tolerated therapeutic option for patients with relapsing multiple sclerosis.

These results position fenebrutinib as a promising oral therapy that delivers superior lesion reduction compared to placebo while maintaining an acceptable safety profile. The sustained low relapse rates observed during the extension phase further support its potential as an effective disease-modifying treatment for relapsing MS patients, with the convenience of oral administration offering advantages over intravenous therapies.

Fenebrutinib's Unique BTK Inhibition for MS

Bruton's tyrosine kinase (BTK) inhibitors represent a promising novel therapeutic class for relapsing multiple sclerosis, targeting both B cells and microglia with dual immunomodulatory effects and central nervous system penetration. Fenebrutinib, a highly selective, noncovalent, reversible BTK inhibitor, demonstrated significant efficacy in the phase 2 FENopta trial conducted across 18 centers in Europe and North America. In this randomized controlled study of 109 patients, fenebrutinib 200 mg twice daily achieved a 69% relative reduction in new T1 gadolinium-enhancing lesions compared to placebo (p=0.0022), with sustained effects through the open-label extension where 96% of patients remained relapse-free at week 48. The safety profile was favorable, with hepatic enzyme elevations, headache, and nasopharyngitis as the most common adverse events, and no serious adverse events or deaths reported.

Other emerging BTK inhibitors show similar promise, with tolebrutinib demonstrating dose-dependent efficacy in reducing gadolinium-enhancing and T2 lesions at optimal doses of 60 mg daily, while evobrutinib showed dose-dependent decreases in serum neurofilament light levels and relapse rates with twice-daily dosing. Meta-analysis data comparing BTK inhibitors to teriflunomide across four randomized controlled trials involving 4,136 participants revealed that BTK inhibitors reduced the risk of 3-month confirmed disability worsening (HR: 0.81; 95% CI: 0.67-0.97) while maintaining comparable annualized relapse rates and serious adverse event profiles.

Ninjurin-1 (nerve injury-induced protein 1) has emerged as a novel therapeutic target, identified as a key mediator of immune activation and CNS infiltration in experimental autoimmune encephalomyelitis models of relapsing-remitting MS. This adhesion molecule is markedly upregulated on CNS-infiltrating myeloid cells during disease progression, with Ninjurin-1+ myeloid cells displaying dual functionality as both adhesion molecules and inflammatory activation markers. These cells demonstrate increased antigen presentation, cytokine production, and transcriptional enrichment for genes regulating adhesion, migration, and innate immune signaling. Therapeutic blockade of Ninjurin-1 significantly reduced clinical severity, CNS immune infiltration, and demyelination in preclinical models, highlighting its potential as a therapeutic target for myeloid-driven neuroinflammation in relapsing-remitting MS.

Assessing Fenebrutinib's Safety and Tolerability Profile

Published safety and tolerability data for fenebrutinib across multiple indications demonstrates a generally favorable profile compared to other BTK inhibitors. Clinical studies spanning rheumatoid arthritis, chronic spontaneous urticaria, systemic lupus erythematosus, and multiple sclerosis provide evidence of acceptable tolerability, though some dose-dependent hepatic effects have been observed.

• Most common adverse events include nausea, headache, anemia, and upper respiratory tract infections, with an overall safety profile consistent with existing immunomodulatory therapies for rheumatoid arthritis

• Hepatic safety considerations emerged in chronic spontaneous urticaria trials, where asymptomatic, reversible grade 2 and 3 liver transaminase elevations occurred in patients receiving fenebrutinib 150 mg daily and 200 mg twice daily (2 patients in each group)

• Cardiovascular safety profile appears favorable, with cardiac safety studies in multiple sclerosis patients showing both therapeutic (400 mg) and supratherapeutic (700 mg) doses had no clinically meaningful impact on QT interval and maximum observed ΔQTcF values of 5.3 ms and 8.2 ms respectively

• Notable absence of bleeding complications distinguishes fenebrutinib from irreversible BTK inhibitors like ibrutinib, acalabrutinib, zanubrutinib, and tirabrutinib, with no bleeding events reported across clinical trials

• Drug interaction safety was demonstrated in combination with methotrexate, where fenebrutinib 200 mg twice daily plus methotrexate 7.5 mg showed no clinically significant pharmacokinetic interactions and was well tolerated in healthy subjects

• Dose-dependent tolerability patterns were observed in systemic lupus erythematosus studies, where serious adverse events occurred more frequently with fenebrutinib 200 mg twice daily compared to 150 mg once daily or placebo

Addressing Persistent Unmet Needs in Relapsing MS

Recent literature identifies several critical areas where relapsing multiple sclerosis (RMS) treatment remains inadequate despite therapeutic advances. While current disease-modifying therapies effectively reduce relapse frequency, significant gaps persist in addressing disease progression, neurodegeneration, and long-term outcomes. The field is actively targeting specific patient populations and therapeutic challenges that represent the most pressing unmet medical needs.

• Progressive disease components remain inadequately addressed, as current DMTs rarely stop long-term progression or repair neurological damage, with relapse-independent progression continuing despite reduced inflammatory activity

• Long-term efficacy and safety data beyond two years is insufficient for chronic disease management, creating uncertainty about decades-long treatment strategies and optimal therapeutic duration

• Neurodegeneration and brain atrophy persist even with effective anti-inflammatory treatments, particularly in secondary progressive MS patients who show higher baseline atrophy rates (61.1% vs 25.0% in RRMS patients)

• Treatment-naïve patients represent a critical target population (59.7% of real-world cohorts), with early initiation of high-efficacy DMTs showing significant clinical impact on long-term disability outcomes

• Patients requiring treatment switches due to breakthrough disease activity or safety/tolerability issues need optimized sequencing strategies, as treatment effectiveness decreases with later therapy lines

• Resource-poor settings lack access to approved therapies, necessitating research into off-label alternatives like rituximab biosimilars, azathioprine, and mycophenolate mofetil despite regulatory and payer barriers

• Patient-relevant outcomes including quality of life, cognitive status, and sex/gender-specific treatment effects require greater research focus beyond traditional clinical measures

A New Oral Frontier in Multiple Sclerosis Therapy

The recent positive Phase III results for fenebrutinib mark a significant moment in the treatment landscape for multiple sclerosis, particularly for patients with relapsing forms. The investigational non-covalent BTK inhibitor demonstrated a substantial reduction in annualised relapse rates, exceeding 50% compared to an active comparator, alongside improvements in brain lesion activity and positive trends in reducing disability progression. This robust efficacy, coupled with its oral administration, positions fenebrutinib as a potentially transformative option, offering both convenience and potent disease control. The planned regulatory submissions for both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) underscore a strategic ambition to address a broad spectrum of patient needs, potentially establishing fenebrutinib as a foundational therapy across the disease continuum. This broad applicability could significantly enhance its market penetration and impact.

However, as with any novel therapeutic agent, a comprehensive understanding of its long-term safety profile will be paramount. While the current data highlights efficacy, the broader literature on novel therapies in other indications suggests the importance of vigilance for rare, severe adverse events. For instance, therapy-related myeloid neoplasms (t-MN) have been observed as a rare complication with other novel agents, characterized by specific cytogenetic aberrations such as complex karyotypes, del7q/-7, and del5q/-5, and molecular alterations like TP53 mutations. The latency period for such complications can extend over several years, with some cases emerging within two years, emphasizing the need for sustained, long-term safety surveillance in the post-marketing phase. This vigilance is crucial to fully characterize the benefit-risk profile in a real-world setting.

The successful development of fenebrutinib could also have broader implications for the BTK inhibitor class, further validating its potential in neuroinflammatory conditions. This success may spur additional research and development efforts into similar mechanisms, potentially expanding the therapeutic arsenal for multiple sclerosis and other autoimmune diseases. As the pharmaceutical industry continues to innovate, balancing high efficacy with a favorable safety profile remains a critical challenge, and ongoing monitoring will be essential to fully characterize fenebrutinib's role in patient care and its long-term impact on the MS treatment paradigm.